Cannabidiol trial shows reduction in seizures for children with Dravet syndrome

30 May 2017, 12:58 p.m.

A woman is stood smiling at the camera in a red jacket and shelves of dossiers behind her.

A trial conducted in Europe and the USA has shown that cannabidiol – a drug derived from cannabis but with the psycho-active elements removed – reduces seizures in children with a form of drug resistant epilepsy, known as Dravet syndrome.

The study was led by NIHR GOSH BRC cross cutting theme lead Professor Helen Cross, in collaboration with New York University.

In the trial one hundred and twenty children with Dravet syndrome across Europe and the USA were given two daily doses of cannabidiol orally for fourteen weeks. At the end of the study the average number of severe seizures reduced by nearly 40%. For 5% of patients, seizures stopped completely.

The research, Trial of Cannabidiol for Drug-Resistant seizures in the Dravet Syndrome, was published in the New England Journal of Medicine.

Read the press release.

Dr Ian Simcock becomes GOSH’s first Allied Health Professional to receive NIHR postdoctoral fellowship

The five-year fellowship will focus on improving parental choice after pregnancy loss through the development of less-invasive post-mortem investigations.

National conference brings child health research community together

Researchers and clinicians from across the UK gathered at Sheffield City Hall for the inaugural National Paediatric Translational Research Conference

Mum chooses to support research as a legacy for her twins

Understanding how a singular cancer spread between two twins in the womb using genomics - Research from GOSH and the Sanger Institute

World-first same-day metagenomics for children can detect hidden infections in intensive care

GOSH has successfully implemented a pioneering same-day respiratory metagenomics testing service for children in intensive care, helping clinicians identify infections more quickly and make better-informed treatment decision